Healthcare provider profile · identity verified

Alfred D Arline, MD

Family Practice · PUEBLO, CO · NPI 1174585749

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	540	161
Amlodipine Besylate	Amlodipine Besylate	454	134
Lisinopril	Lisinopril	394	122
Levothyroxine Sodium	Levothyroxine Sodium	262	80
Metformin Hcl	Metformin Hcl	227	68
Losartan Potassium	Losartan Potassium	220	70
Omeprazole	Omeprazole	220	85
Tamsulosin Hcl	Tamsulosin Hcl	197	74
Rosuvastatin Calcium	Rosuvastatin Calcium	169	52
Simvastatin	Simvastatin	145	41
Gabapentin	Gabapentin	137	41
Jardiance	Empagliflozin	137	35
Albuterol Sulfate Hfa	Albuterol Sulfate	131	57
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	127	21
Metoprolol Succinate	Metoprolol Succinate	125	44
Tramadol Hcl	Tramadol Hcl	119	27
Oxycodone Hcl	Oxycodone Hcl	110	13
Doxazosin Mesylate	Doxazosin Mesylate	103	26
Allopurinol	Allopurinol	101	29
Hydrochlorothiazide	Hydrochlorothiazide	99	30
Pantoprazole Sodium	Pantoprazole Sodium	97	31
Glipizide	Glipizide	92	27
Pradaxa	Dabigatran Etexilate Mesylate	92	30
Finasteride	Finasteride	91	33
Wixela Inhub	Fluticasone Propion/Salmeterol	89	33
Escitalopram Oxalate	Escitalopram Oxalate	85	36
Furosemide	Furosemide	84	31
Metoprolol Tartrate	Metoprolol Tartrate	82	28
Sertraline Hcl	Sertraline Hcl	82	23
Potassium Chloride	Potassium Chloride	76	28
Alendronate Sodium	Alendronate Sodium	73	25
Ozempic	Semaglutide	68	suppressed
Meloxicam	Meloxicam	67	25
Carvedilol	Carvedilol	64	22
Mirtazapine	Mirtazapine	63	31
Morphine Sulfate Er	Morphine Sulfate	63	suppressed
Fluticasone Propionate	Fluticasone Propionate	59	21
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	59	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	18
Metformin Hcl Er	Metformin Hcl	57	19
Trazodone Hcl	Trazodone Hcl	56	24
Shingrix	Varicella-Zoster Ge/As01b/Pf	55	51
Spiriva Respimat	Tiotropium Bromide	55	17
Clopidogrel	Clopidogrel Bisulfate	53	20
Atenolol	Atenolol	52	14
Azelastine Hcl	Azelastine Hcl	50	23
Duloxetine Hcl	Duloxetine Hcl	48	21
Montelukast Sodium	Montelukast Sodium	47	17
Ondansetron Hcl	Ondansetron Hcl	47	suppressed
Warfarin Sodium	Warfarin Sodium	46	15
Famotidine	Famotidine	44	11
Spironolactone	Spironolactone	44	15
Humulin N	Insulin Nph Human Isophane	43	13
Naloxone Hcl	Naloxone Hcl	38	25
Pioglitazone Hcl	Pioglitazone Hcl	38	15
Prednisone	Prednisone	37	23
Baclofen	Baclofen	35	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	35	suppressed
Clonazepam	Clonazepam	32	suppressed
Lactulose	Lactulose	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	30	30
Chlorthalidone	Chlorthalidone	30	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	29	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	28	suppressed
Oxycontin	Oxycodone Hcl	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	13
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	26	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	12
Bupropion Xl	Bupropion Hcl	22	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Torsemide	Torsemide	21	suppressed
Cefuroxime	Cefuroxime Axetil	20	20
Eliquis	Apixaban	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Humalog	Insulin Lispro	19	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	17
Benazepril Hcl	Benazepril Hcl	17	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Breyna	Budesonide/Formoterol Fumarate	16	suppressed
Alvesco	Ciclesonide	15	suppressed
Brilinta	Ticagrelor	15	suppressed
Humulin R	Insulin Regular, Human	15	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	14
Acyclovir	Acyclovir	13	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	13	13
Lorazepam	Lorazepam	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	12
Nitroglycerin	Nitroglycerin	12	suppressed
Nystatin	Nystatin	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error